HomeAI · summaries
Storia in 17 fonti
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
mediapart.fr
Cancer: GSK annonce le rachat de l’américain Nuvalent pour 10,6 milliards de dollars
Le géant pharmaceutique britannique GSK a annoncé mardi un accord pour acquérir la société biopharmaceutique américaine Nuvalent, spécialisée dans le développement de thérapies…
- ·
cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
